Because Your Research Counts

Our mission is to bring cutting-edge medicine to patients. We will support your biologics project via the breadth of our offered platforms, from lead identification to clinical candidate selection.

Collaboration is key to creating optimal outcomes for current and future patients. Precision medicine, orphan diseases and improving current treatments are all common themes within our industry. Understanding the science and biology behind a disease is critical for the successful development of therapeutic drugs.



We offer prediction tools. Profiling your CARs or mAbs effects in the context of complex disease-relevant assays can identify fully optimized and differentiated candidates for progression to first in-human trials. Informing possible on-target off-tissue effect or measure unpredictable off-target in humans is critical to allow early decision before proceeding with animal models. The right level of affinity, a solid understanding of the biology and highly developable leads are critical for success.



“Many antibodies fail in the clinic because they aren’t efficacious enough, but around 20% fail because they’re just not developable as therapeutics.”

-Lorraine Thompson, Principal Scientist at Charles River. 



Over the past three years more than 80% of FDA approved drugs on the market were created, developed or worked on by Charles River. We have 22 years of experience in integrated projects with 85 pre-clinical candidates delivered in the small molecule world. In conjunction with our state-of-the-art biologics libraries, we provide expertise in multiple therapeutic areas and target classes. Our method is to deliver a holistic approach for your CAR and mAb projects. 



We host a team of seasoned professionals to support your project from the lead isolation to pre-clinical candidate selection. Starting with a solid foundation at the initial phases of discovery will pave the way to your success. Charles River acquired Distributed Bio to provide you with a unique diverse library comprising human frameworks selected for exceptional thermal stability to enhance developability. In addition to largescale diversity, CDRs were selected amongst antibodies tested in Phase I, and therefore, reduces clinical risk.


Find the key to your success.

Get started

Our CAR and Antibody Project Solutions

  • Libraries for Lead Finding

    Our antibody libraries for lead finding are suited for all target classes including ion channels, GPCRs, anti-ids, HIV, allosterics, and anti-pMHCs but are especially well-suited for CARs. When compared with mouse immunization, our SuperHuman phage display library enables rapid scFv and VHH discovery. Learn more

  • Off-target Testing

    Off target screening using micro-array based technology offering the largest, most unique and high-quality set of human cell surface and secreted proteins (>6,200) expressed in human cells. Learn more

  • On-target Off-tissue Screening
    • Tissue distribution of your target is critical to inform the decision about potency. We can screen databases to evaluate this risk using bioinformatics. Learn more

    • A CAR-T or cellular therapy must demonstrate on-target efficacy, but preclinical evaluations must also assess off-target or on-target/off-tumor activity. Learn more

  • Predictive Immunotox Assays

    Our extensive predictive immunotoxicology range of assays allows you to work with our scientists to build a tailored program for your therapeutic, suitable for each stage of development. Amongst the tools we have well established assays, such as infusion-related reaction assays, modification of innate immune function and differentiation, and modification of adaptive immune function and differentiation. Learn more

  • In Vitro Testing

    Success in the clinic begins with identification, characterization and validation using a comprehensive panel of in vitro assays. Our assay development services provide translational insights from target discovery to expression. Using patient-derived cells and gene editing tools, we have proven efficacy in a variety of therapeutic areas. Learn more